title: [Experience with simvastatin therapy for the achievement of osteoprotective effects in women with hyperlipidemia].
abstract: The aim of the work was to study the influence of statins on the functional and metabolic state of bone tissue during correction of type IIA and IIB hyperlipidemia in women with osteopenia. 53 of the 83 patients aged 45-50 years were treated with statins (20 mg/d) and low-fat diet. Bone mineral density (BMD) was measured in the lumbar spine region (LII-LIV) and femoral neck by DEXA. Simultaneously the lipid profile and serum bone metabolism markers (osteocalcin, beta-CrossLaps CL) were detected. Simvastatin therapy led to normalization of osteocalcin level (p<0.01) within 6 months. In the control group, it remained unaltered and tended to decrease after 12 months (p>0.05). The level of bone resorption marker (CL) dropped within 3 months after the onset of therapy (p<0.050) and continued to decrease by the 12th month (p<0.05). It was significantly lower than in controls (p<0.05) both after 6 and 12 months. BMD in the femoral neck and LII-LIV increased by 2.2 and 2.6% respectively after 12 months of simvastatin therapy and by 1.4 and 1.7% after consumption of low-fat diet. It is concluded that simvaststin therapy (20 mg/d) during 12 months has positive effect on bone metabolism during treatment of atherogenic hyperlipidemia in patients with osteopenia.
authors.forename: E F
authors.initials: EF
authors.lastname: Semisotova
authors.forename: E A
authors.initials: EA
authors.lastname: Kochetkova
authors.forename: I N
authors.initials: IN
authors.lastname: Kiriliuk
mesh_terms: D015502:Absorptiometry, Photon; D001682:Biological Availability; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism; D001862:Bone Resorption / Q000188:drug therapy* / Q000378:metabolism; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D003094:Collagen / Q000097:blood; D018752:Diet, Fat-Restricted; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D020011:Protective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D019821:Simvastatin / Q000008:administration & dosage / Q000493:pharmacokinetics; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D000960:Hypolipidemic Agents; D008055:Lipids; D010446:Peptide Fragments; D020011:Protective Agents; C110762:glutamyl-lysyl-alanyl-histidyl-aspartyl-glycyl-glycyl-arginine; D015675:Osteocalcin; D003094:Collagen; D019821:Simvastatin